Amgen Inc on Wednesday said it filed with U.S. health regulators seeking approval to sell its first biosimilar drug, which would be a less expensive alternative to AbbVie's Humira, the world's top-selling prescription medicine.
Amgen said its drug, ABP 501, has demonstrated clinical equivalence and comparable safety to Humira (adalimumab) in late stage clinical trials for rheumatoid arthritis and the skin condition plaque psoriasis.
02:10 Attorney General's office announces settlement with drug manufacturer9
09:43 ThyssenKrupp secrets stolen in 'massive' cyber attack this year22
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle21
14:47 Gambian president said he would rule for a ‘billion years.’ He just lost reelection16